[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Taysha Gene Therapies Inc (TSHA)

Taysha Gene Therapies Inc (TSHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,919,571
  • Shares Outstanding, K 287,361
  • Annual Sales, $ 9,770 K
  • Annual Income, $ -109,000 K
  • EBIT $ -110 M
  • EBITDA $ -109 M
  • 60-Month Beta 1.22
  • Price/Sales 187.30
  • Price/Cash Flow N/A
  • Price/Book 8.64

Options Overview Details

View History
  • Implied Volatility 96.50% (+3.68%)
  • Historical Volatility 74.59%
  • IV Percentile 13%
  • IV Rank 14.46%
  • IV High 245.50% on 03/03/26
  • IV Low 71.32% on 08/20/25
  • Expected Move (DTE 8) 0.67 (10.48%)
  • Put/Call Vol Ratio 0.26
  • Today's Volume 59
  • Volume Avg (30-Day) 288
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 11,294
  • Open Int (30-Day) 13,618
  • Expected Range 5.74 to 7.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.12
  • Number of Estimates 2
  • High Estimate $-0.11
  • Low Estimate $-0.12
  • Prior Year $-0.09
  • Growth Rate Est. (year over year) -33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.28 +21.30%
on 07/28/26
6.75 -5.11%
on 08/11/26
+0.07 (+1.03%)
since 07/10/26
3-Month
5.17 +23.89%
on 05/20/26
7.12 -10.04%
on 06/30/26
-0.44 (-6.50%)
since 05/12/26
52-Week
2.71 +136.29%
on 09/22/25
7.30 -12.26%
on 05/06/26
+3.50 (+120.10%)
since 08/12/25

Most Recent Stories

More News
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6 ‑ month interim analysis and FDA feedback on the BLA...

TSHA : 6.41 (-4.12%)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based...

TSHA : 6.41 (-4.12%)
Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

DALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based...

TSHA : 6.41 (-4.12%)
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

CAMBRIDGE, Mass. and DALLAS and TAMPA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc., (Nasdaq: TSHA) (Taysha), a clinical-stage biotechnology company focused on developing adeno-associated...

TSHA : 6.41 (-4.12%)
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting

Recently disclosed longer-term REVEAL Part A data demonstrated broad, multi-domain functional impact that deepened over time through ≥12 months post-TSHA-102 regardless of age or disease severity ...

TSHA : 6.41 (-4.12%)
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based...

TSHA : 6.41 (-4.12%)
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based...

TSHA : 6.41 (-4.12%)
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome

Completed dosing of 17 patients in REVEAL pivotal trial; topline data from 6 ‑ month interim analysis and FDA feedback on next steps toward BLA submission pathway expected 1H 2027 TSHA-102 was...

TSHA : 6.41 (-4.12%)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based...

TSHA : 6.41 (-4.12%)
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following recent...

TSHA : 6.41 (-4.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104...

See More

Key Turning Points

3rd Resistance Point 7.00
2nd Resistance Point 6.73
1st Resistance Point 6.57
Last Price 6.41
1st Support Level 6.13
2nd Support Level 5.85
3rd Support Level 5.69

See More

52-Week High 7.30
Last Price 6.41
Fibonacci 61.8% 5.55
Fibonacci 50% 5.01
Fibonacci 38.2% 4.46
52-Week Low 2.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.